<DOC>
	<DOCNO>NCT00246415</DOCNO>
	<brief_summary>The purpose study obtain preliminary indication safety effectiveness oral memantine ( 40 mg/day ) alcohol dependent patient . This study 16-week study comparison memantine placebo patient alcohol dependence .</brief_summary>
	<brief_title>A Placebo-Controlled Trial Memantine Alcohol Dependence</brief_title>
	<detailed_description>This study 16-week study , double-blind , parallel group , two arm comparison memantine placebo patient alcohol dependence . Procedures . This outpatient clinical trial comprise 2-week placebo lead-in phase follow 12-week treatment phase 2-week lead-out phase . Patients see 2x/week . There also 3-month follow-up visit reassess status abstinence relapse drinking . The design study follow : Single-blind Placebo Lead-in Phase ( Week -2 Week -1 ) . Patients give informed consent provisionally meet inclusion-exclusion criterion enter 2-week Single-blind Placebo Lead-in Phase . After placebo lead-in phase , patient randomize receive memantine placebo stratify sex , age , race level alcohol dependence . 12 Week Treatment Phase ( Weeks 1-12 ) . At visit , medication provide , standardized assessment instrument complete , biochemical measure take monitor alcohol consumption well compliance study medication . In one two weekly visit patient receive individual , manual-guided relapse prevention therapy clinician meet study psychiatrist . Patients wish take naltrexone ( ReVia ) , disulfiram ( Antabuse ) , participate intensive inpatient treatment trial discontinue study . Single-blind Lead-out Phase ( Weeks 13-14 ) . During 2-week lead-out phase , patient active medication taper medication placebo , measure assessment ( include weekly psychotherapy session ) remain . All patient , regardless whether complete study administratively remove , follow rat Week 14 . There also 3-month follow-up visit reassess status abstinence relapse drinking . Clinic Visits . During visit , research nurse research assistant measure breath alcohol content ( BAC ) , urine blood sample schedule monitoring alcohol , illicit drug use , medication compliance . Medication compliance initially assess measure riboflavin fluorescence urine sample . The staff supervise completion self-report questionnaire . The nurse check vital sign visit , weight per week question patient compliance , miss dos , possible side effect adverse event , complete compliance adverse event form . Medication compliance monitor via riboflavin ( Del Boca et al 1996 ) , self-report data , collateral informant data , medication blood level . Likewise , drink behavior monitor BAC , self-report collateral informant data . This data available treatment team use reinforce importance compliance . The patient meet weekly psychiatrist ass current alcohol use mood status , evaluate side effect adjust dosage need ( use prearrange blind dose adjustment schedule ) , review event occur since last study visit relate patient 's functioning , perform CGI-Observer rating . During one two weekly visit , patient also meet therapist individual relapse prevention therapy . At point trial , treat psychiatrist determines primary alcohol dependence , secondary dependence drug abuse , new drug dependence escalate intensive intervention require , he/she make decision removal trial referral form treatment . Medication give fixed-flexible schedule , titrate maximum recommend dose minimize side effect . Patients receive enough medication last next visit . For patient assigned memantine , gradually titrate 10 mg/day maximal dose 20 mg b.i.d . ( 40 mg/day ) first two week treatment phase . All patient receive match pill quantity day . In case several miss visit , side effect adverse event , study nurse study psychiatrist meet patient dose decrease arrange use prearrange blind dose adjustment schedule . Patients tolerate 50 % maximal dose ( i.e. , 20 mg/day memantine ) discontinue study medication ; however , base experience , highly unlikely .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>1 . Males female age 1865 yr . 2 . Meets DSMIV criterion current alcohol dependence . Volunteers may meet criterion substance abuse , dependence drug ( nicotine , marijuana cocaine ) long dependence marijuana cocaine secondary alcohol dependence 3 . Medically healthy basis physical examination medical history , vital sign , ECG laboratory test , negative blood pregnancy test female . 4 . Expresses desire stop drinking alcohol . 5 . Does require psychotropic medication . 6 . Able provide inform consent comply study procedure . 7 . Signed informed consent . 1 . Dependence opiates 2 . Meets DSMIV criterion schizophrenia bipolar Disorder . Has psychotic illness risk suicidal behavior . 3 . History delerium tremens ( hallucination , psychosis , agitation ) secondary alcohol withdrawal , personal family history seizure disorder , personal history moderate/severe head trauma . 4 . Currently take psychotropic medication . 5 . In need inpatient alcohol detoxification . 6 . Any renal disease insufficiency . 7 . Clinically significant symptomatic medical disorder require active intervention 8 . Female patient lactate childbearing potential refuse use birth control ( hormone barrier ) pregnant . 9 . Patients treatment alcoholism mandate legal action . 10 . Patients active malignancy ( non melanoma skin cancer carcinoma situ uterine cervix ) within 5 year begin study . 11 . Known suspected hypersensitivity memantine . 12 . Intolerable adverse event Single Blind Placebo Leadin Phase . 13 . Patients take naltrexone antabuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Alcohol Dependence</keyword>
	<keyword>Alcohol Abuse</keyword>
	<keyword>Memantine</keyword>
	<keyword>Alcohol Treatment</keyword>
</DOC>